Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Esketamine-dexmedetomidine Combination for Postpartum Depression Prevention
NCT07639099Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jun 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine and dexmedetomidine in postpartum depression (PPD) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Prevalence of depressive symptoms. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
esketaminedexmedetomidine
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on NCT07639099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639099.